NCT03048344
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 2, 2016
Completion: Feb 28, 2019